Abiopharma

New Form 424B5 - ASSEMBLY BIOSCIENCES, INC. Filed: 2025-08-11 AccNo: 0001193125-25-177435 Size: 636 KB

I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

New Form SCHEDULE 13G - ARROWHEAD PHARMACEUTICALS, INC. Filed: 2025-08-11 AccNo: 0000093751-25-000436 Size: 8 KB

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Harvard Bioscience Announces Second Quarter 2025 Financial Results

New Form 8-K - HARVARD BIOSCIENCE INC Filed: 2025-08-11 AccNo: 0001171843-25-005262 Size: 376 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - BIOXYTRAN, INC Filed: 2025-08-11 AccNo: 0001493152-25-011797 Size: 7 MB

New Form 10-Q - Compass Therapeutics, Inc. Filed: 2025-08-11 AccNo: 0001171843-25-005261 Size: 5 MB

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

BioCryst Announces Departure of Dr. Helen Thackray

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome